Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
ART4215 is a potentially first-in-class, highly selective, oral small molecule inhibitor targeting the Polθ polymerase…